HER2DX与HER2阳性乳腺癌病理完全缓解及生存结局的关联
研究评估HER2DX基因组检测与早期HER2阳性乳腺癌新辅助治疗后病理完全缓解(pCR)及生存结局的关联。汇总7个新辅助队列数据,HER2DX pCR评分与pCR显著相关(每增加10单位OR=1.59,95%CI 1.43-1.77;AUC=0.75)。调整pCR状态后,HER2DX低风险患者EFS(P<0.001)和OS(P=0.006)优于高风险患者。
要点
- HER2DX pCR评分与pCR显著相关,每增加10单位OR=1.59(95%CI 1.43-1.77),AUC=0.75。
- HER2DX pCR-high肿瘤化疗基础上双靶向较大曲妥珠单抗单靶显著提高pCR率(OR=2.36,95%CI 1.09-5.42)。
- HER2DX pCR-low肿瘤pCR率≤30.0%,无论采用何种治疗。
核心结论
- HER2DX pCR评分和风险评分可能有助于识别适合接受新辅助双靶向HER2阻断联合单药紫杉类治疗的早期HER2阳性乳腺癌理想候选者。
研究设计与样本
- 评估7个新辅助队列(DAPHNe、GOM-HGUGM-2018-05、CALGB-40601、ISPY-2、BiOnHER、NEOHER和PAMELA)中具有HER2DX和临床个体患者数据者。
- 所有患者接受新辅助曲妥珠单抗(n=765),联合帕妥珠单抗(n=328)、拉帕替尼(n=187)或不联合第二种抗HER2药物(n=250)。
- NEOHER和PAMELA合并系列共268例患者(pCR者n=118,非pCR者n=150)有EFS和OS结局数据。
- 采用Cox模型调整分析HER2DX能否在pCR状态之外识别低风险或高风险患者。
主要发现
- HER2DX pCR评分与所有患者pCR显著相关(每增加10单位OR=1.59,95%CI 1.43-1.77;ROC曲线下面积=0.75),无论是否联合双靶向HER2阻断。
- 在HER2DX pCR-high肿瘤接受化疗者中,双靶向HER2阻断较曲妥珠单抗单靶显著提高pCR率(OR=2.36,95%CI 1.09-5.42)。
- 在HER2DX pCR-medium肿瘤接受双靶向HER2阻断者中,多药化疗较单药紫杉类显著提高pCR率(OR=3.11,95%CI 1.54-6.49)。
- HER2DX pCR-low肿瘤的pCR率≤30.0%,无论采用何种治疗。
- 调整pCR状态后,HER2DX低风险患者较高风险患者EFS更优(P<0.001)、OS更优(P=0.006)。
关键数值与推荐
- HER2DX pCR评分每增加10单位与pCR的OR=1.59(95%CI 1.43-1.77;AUC=0.75)。
- HER2DX pCR-high肿瘤化疗者中双靶向较曲妥珠单抗单靶的pCR率OR=2.36(95%CI 1.09-5.42)。
- HER2DX pCR-medium肿瘤双靶向者中多药化疗较单药紫杉类的pCR率OR=3.11(95%CI 1.54-6.49)。
- HER2DX pCR-low肿瘤pCR率≤30.0%。
- 调整pCR状态后HER2DX低风险较高风险EFS的P<0.001、OS的P=0.006。
临床怎么用
- 作者认为HER2DX pCR评分和风险评分可能有助于识别适合接受新辅助双靶向HER2阻断联合单药紫杉类治疗的早期HER2阳性乳腺癌理想候选者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The HER2DX genomic test predicts pathological complete response (pCR) and survival outcome in early-stage HER2-positive (HER2+) breast cancer. Here, we evaluated the association of HER2DX scores with (i) pCR according to hormone receptor status and various treatment regimens, and (ii) survival outcome according to pCR status. MATERIALS AND METHODS: Seven neoadjuvant cohorts with HER2DX and clinical individual patient data were evaluated (DAPHNe, GOM-HGUGM-2018-05, CALGB-40601, ISPY-2, BiOnHER, NEOHER and PAMELA). All patients were treated with neoadjuvant trastuzumab (n = 765) in combination with pertuzumab (n = 328), lapatinib (n = 187) or without a second anti-HER2 drug (n = 250). Event-free survival (EFS) and overall survival (OS) outcomes were available in a combined series of 268 patients (i.e. NEOHER and PAMELA) with a pCR (n = 118) and without a pCR (n = 150). Cox models were adjusted to evaluate whether HER2DX can identify patients with low or high risk beyond pCR status. RESULTS: HER2DX pCR score was significantly associated with pCR in all patients [odds ratio (OR) per 10-unit increase = 1.59, 95% confidence interval 1.43-1.77; area under the ROC curve = 0.75], with or without dual HER2 blockade. A statistically significant increase in pCR rate due to dual HER2 blockade over trastuzumab-only was observed in HER2DX pCR-high tumors treated with chemotherapy (OR = 2.36 (1.09-5.42). A statistically significant increase in pCR rate due to multi-agent chemotherapy over a single taxane was observed in HER2DX pCR-medium tumors treated with dual HER2 blockade (OR = 3.11, 1.54-6.49). The pCR rates in HER2DX pCR-low tumors were ≤30.0% regardless of treatment administered. After adjusting by pCR status, patients identified as HER2DX low-risk had better EFS (P < 0.001) and OS (P = 0.006) compared with patients with HER2DX high-risk. CONCLUSIONS: HER2DX pCR score and risk score might help identify ideal candidates to receive neoadjuvant dual HER2 blockade in combination with a single taxane in early-stage HER2+ breast cancer.
引用
- Villacampa G, Tung NM, Pernas S, et al. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Ann Oncol. 2023. PMID: 37302750. doi:10.1016/j.annonc.2023.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。